In the era of new targeted therapies, including BTKi [82, 83] and CD19-directed CAR-T cells [81, 84], every case of MCL should be investigated prior therapy for morphology (blastoid/pleomorphic variant) (Fig. 1C), immunophenotype, proliferative index (labeling of Ki67) (Fig. 1D) and presence of TP53 deletions/mutations since the occurrence of one or more of these variables associates with a poor prognosis [81, 85]. This evidence concerns the gene TP53 and mantle cell lymphoma.